SHILPAMED Shilpa Medicare Q2 FY26 results (Jul–Sep 2025) and concall
Shilpa Medicare delivered a strong Q2 FY26, achieving its highest-ever quarterly EBITDA of ₹110 crores on revenues of ₹372 crores, driven by robust performance in API and Formulation segments. The company successfully launched its first NCE program, NorUrsodeoxycholic acid, in India and continues to advance a complex pipeline across API, Formulations, and Biologics. Despite positive financial results and strategic progress, specific updates on the USFDA inspection for the Jadcherla plant remain undisclosed.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 3.8%, net profit up 3.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 130 | 125 | 126 | 92 | 135 +4% |
| EBITDA | 43 | 22 | 38 | 17 | 39 −9% |
| Net profit | 30 | 16 | -6 | 21 | 31 +3% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
